PREDICT
LIFE CARE

PREDICT S.p.A.

Investor Presentation

9th October 2026

IR TOP Lugano Investor Day 2026

AT A GLANCE

Hi-Tech solutions for advanced diagnostics

Predict S.p.A., based in Bari, is an innovative SME active in the med-tech sector, specializing in non-invasive in vivo diagnostics. It markets medical imaging systems for screening, providing technical assistance, and develops innovative technologies in the fields of ***breath analysis*** and ***digital healthcare***.

~20 years of partnership with GE HealthCare

33 Highly qualified employees*

*As of 30/06/2026

€0.84 mn invested in R&D in 2025

3 patents

4 Strategic Business Units

Traditional

Imaging

Distribution of **diagnostic equipment** (for ultrasound, X-rays, and magnetic resonance imaging).Training of healthcare personnel.



People Support

Technical assistance and after-sales services, maintenance, repair, and add-ons. **Predictive healthcare** and hospital **disinfection solutions**.



Innovative

Mistral

Development and sale of advanced **breath analysis** solutions for the early screening of diseases.



Digital Healthcare

Development and sale of **innovative** solutions in augmented reality, holography, and collaborative **robotics** to improve healthcare services.



PREDICT LIFE CARE

MILESTONES

2008
PREDICT WAS FOUNDED

2008
SUBSCRIPTION OF AGENCY MANDATE FOR GE

2012
AFTER-SALES SERVICES FOR GE MACHINERY

2016 - 2018
MISTRAL, OPTIP & APHEL DEVELOPING

2020
FIRST ROBOT INSTALLATION

2021
DELIVERY OF FIRST SAMPLER

2023
OPTIP STAGE AND MISTRAL LAB

2024
INNOVATIVE SME AND IPO ON EGM

2025
NEW OFFICES OPENING OUT | TEAM EXPANSION

DISTRIBUTION AGREEMENTS
Shenzhen Spinq | Airs Medical EU | UVC Solutions | Caresmed

ORDERS/CONTRACTS
2 Mistral Samplers+services (IRCCS Bari) | MQ Analyzer (DIF Bari) | 2 Mistral Samplers PoliBA | 3 Robots Corporea Museum (NA) | LiberAUT Project | RTI Tender «AMiCa» | Fetal ultrasound «IAUSO» | Exprivia RTI Tender ICT services «InnovaPuglia»

CALLS
PNRR S4D Precision Diagnostic | PNC D3-4Health

TRIALS
EMICENTER Project | ASMA Trial (Foggia) | Head-neck cancer study (IFO Roma)

START-UP

RESEARCH AND DEVELOPMENT

CONSOLIDATION AND INNOVATION

2026

AGREEMENTS
- Weatecho (Hospital 4.0)
- Robocore Technology
- GE HealthCare renewal
- Luso Electronics (UK, breath analysis)

ORDERS/CONTRACTS
- Niguarda tele-ultrasound platform, OPTIP Bodycam for ASL Foggia, 11 ultrasound scanners for ASL BAT, Hermes Robot for Casa Sollievo della Sofferenza

CALL&TRIALS
Studies: Mistral occupational medicine (automotive) at **COM** (MI), **RECAP** at Sant'Orsola Bologna, pediatric tele-ultrasound at Buzzi (MI)
- **PIA** Project (**C.U.R.E.S.**)
- **STEP** (R.E.S.P.I.R.A) tender

PREDICT LIFE CARE

INDUSTRY BUSINESS SYSTEM AND BUSINESS MODEL

Predict offers a model based on the supply of innovative and high-tech solutions for the healthcare sector, ensuring a favorable ecosystem for widespread technological innovation processes.



4
Strategic Business Units

Imaging	**Mistral**
People Support	**Digital Healthcare**
2 SBU with established solutions to provide **stable & recurring revenues**	**2 SBU** with innovative solutions in **growing markets**

DISRUPTIVE INNOVATION HI-TECH IN THE HEALTHCARE WORLD

The Predict model enables a balanced and efficient management of resources and innovation:

- Each **SBU** has a structured management control system.
- Investments in innovation are planned considering the SBUs and their impact on the business.

STRATEGIC BUSINESS UNITS

The activities of Predict are divided into 4 Strategic Business Units:

Traditional | Innovative

SBU	Imaging	People Support	Mistral	Digital Healthcare
Activity description	• **Sale** of **medical imaging equipment***, marketed in the field of **in vivo diagnostic imaging.** • **Distribution agreements** with GE HealthCare, Fora S.p.A. and Caresmed S.r.l. • **Solutions:** ultrasound systems, X-ray, CT, MRI, PET, mobile units rental services, densitometers and bioimpedance meters • **Med-tech education** and training * new/used, for private customers only	• **Technical support** for the installed **imaging** equipment (installations, calibrations, electrical safety checks) and **repair** (for innovative SBUs) • **Sales** of **spare parts** and **add-ons** • **Predictive Healthcare Solutions MRI** (**AI**) • **Solutions** for the **disinfection** of **hospital environments**	• **Development, design & commercialization** of screening solutions based on proprietary technology for **breath analysis: Mistral Sampler** for VOC sampling, **Mistral Analytics** for medical history. • **Owned Mistral Lab** and the construction of **"turnkey"** breath analysis laboratories for **polyclinics, IRCCS, CRC** • **Clinical trials and prototypes** • **Research partnerships** with universities to evolve and integrate technologies	• **Development and sale** of solutions based on remote communication through augmented reality **(Optip)** and robotics **(Aphel)**, also on active ageing (home robotics services) • **Optip**: Interaction in holographic presence (AR, VR, MR technologies). Holographic stages for training and education. • **Aphel**: AI platform that integrates humanoid and collaborative robots • **Commercialization** of **Quantum computers** in the education & healthcare sector
KPIs	**Revenue** **FY25** **71% → € 5.4 mn** **1H26** **78% → € 3.1 mn**	**Revenue** **FY25** **15% → € 1.2 mn** **1H26** **16% → € 0.7 mn**	**Revenue** **FY25** **3% → € 0.2 mn** **1H26** **0.3% → € 0.01 mn**	**Revenue** **FY25** **11% → € 0.8 mn** **1H26** **5% → € 0.2 mn**



Sample collectors:



PREDICT LIFE CARE

PRODUCTS AND APPLICATION PORTFOLIO

Predict is unique on the national scene, ensuring technological oversight of health data collected through medical devices and the developed equipment.

Traditional

Innovative

SBU

Products

Application areas

Imaging



People Support



Mistral

Mistral Sampler



Mistral LAB



Mistral Analytics



Digital Healthcare

Optip Surgery



Optip Streambox



Optip Probe



Optip Stage



Aphel





Quantum computers distribution

Application areas

ultrasounds

- gynecology
- cardiology
- general imaging
- point of care

X-rays

- mammography

- oncological diseases
- metabolic disorders
- early diagnosis

- tele-ultrasound
- telemedicine
- patient-care
- child neuropsychiatry
- active ageing
- innovative education
- non-pharmacological support
- pediatric oncology & hematology

RESEARCH AND DEVELOPMENT

R&D

Partnership with hospitals, IRCCS, universities

Investments 2019-1H26
€ 5.4mn~

MISTRAL

- **FY24:** Qualitative and semi-quantitative identification of a set of molecules representative of the pathologies investigated; start of clinical trials for other studies
- **FY25:** Clinical trials on asthma, pilot study on head and neck cancers, development of AI-based and machine learning algorithms for major cancers (colorectal, lung, prostate, breast), integration of advanced QEPAS sensors, management software testing
- **2026:** asthma trial completed; development of disease-specific AI algorithms and of a portable sampler; start of the STEP project (R.E.S.P.I.R.A, 36 months); 4 patents by year-end




DIGITAL HEALTHCARE

- **FY24:** Launched project for a robotic system for remote ultrasound; integration of collaborative robotics, computer vision, and deep learning.
- **FY25:** Feedback from ultrasound system installations, AI-assisted box platforms, launch of bodycams in Emergency Departments and ambulance services, introduction of Aphel Alpha Mini, start of the CURES research project
- **2026:** Optip Nuva (AI-assisted ultrasound); pediatric tele-ultrasound at Buzzi Hospital; continuation of CURES (robotics + ultrasound); joint patent filing with UniBA under evaluation




Co-financing for innovation

PIA
Smart Diagnostic System
Contribution: €2.02mn
Period: 10/2021-12/2024

D3-4HEALTH
(Endoscope Project)
Contribution: €266k
Period: 10/2024-04/2026

HEAL ITALIA
Contribution: €212k
Period: 08/2024-11/2025

PIA C.U.R.E.S.
Contribution: TBC
Start: 10/2025

STEP R.E.S.P.I.R.A.
Contribution: TBC
Start: 07/2026

PREDICT LIFE CARE

PATENTS AND CE TRADEMARKS

OPTIP

08/2017
Filing of European patent application

08/2018
Filing of international PCT patent application

12/2019
Filing of CE trademark

02/2020
Filing of CE trademark for the new product release

09/2021
Patent granted in the USA, no. 11,122,164 B2

03/2023
Utility model granted in Italy no. 202023000000231

12/2025
Filing of Italian patent application for Optip Nuva

2026
European patent extension for Optip Nuva

Mistral
INSIDE THE BREATH

12/2018
Filing of International PCT patent application, converted into European patent application no. EP3873347

02/2019
Filing of CE trademark

02/2022
Patent granted and validated in: Spain; Switzerland; Austria; United Kingdom; Germany; Netherlands; France; Italy

10/2025
Filing of a **patent** application for a sampler with real-time VOCs analysis

2026
4 Breath analysis technologies patents to be filed by year-end


PREDICT
LIFE CARE

REFERENCE MARKETS AND DRIVERS

Predict operates in 3 market niches in the Healthcare sector, growing globally:

1 Imaging

At International level




Source: Grand View Research, Medical Imaging Market Size Report, June 2026

In Italy

The ultrasound market in Italy in 2023 was estimated by **COCIR** at **€180 mn**. GE HealthCare has an estimated market share of around 24%, with Predict being the exclusive distributor in Puglia. 42% market share of the market in Apulia estimated for Predict.

2 Breath analysis

At International level




Source: Grand View Research, Breath Analyzers Market Size, Share & Growth Report, 2023

In Italy

Trend**: increase in the demand** for Breath Analysis services as a tool for screening oncological diseases, thanks to the use of **non-invasive** breath biopsy technologies.

3 Digital Health Tech

At International level



Source: Grand View Research, Digital Health Market Size and Share, June 2026

In Italy

Over **€12 billion from the PNRR** allocated to **personnel training** with technologies for **efficiency improvements**, aimed at addressing the staff shortage in the **SSN**

MANAGEMENT TEAM & KEY PEOPLE



Angelo Gigante
Founder, President, CEO

20+ years of experience

2008: founds Predict
2003-2007: sales in GE HealthCare
2000-2003: R&D as Consultant Engineer, software designer
Master's Degree in Electronic Engineering at PoliBa



Isabella Cafagna
Vice President and CEO
Director SBU Mistral, SBU Digital Healthcare

10+ years of experience

2015-today: Sales Account Manager, Sales Manager, SBU Mistral Director for Predict
Master's Degree in Chemistry at UniBA
PhD in Environmental Engineering and Chemistry PoliBa



Loredana Amoruso
CEO
Tender and Legal Affairs Manager

10+ years of experience

2015-today: public tender specialist, legal affair, Legal Department Manager, Tenders Office, Trademarks and Patents for Predict
2009: Registered with the Bar Association of Bari
Master's degree in Law UniBA



Angelo Ceci
Chief Financial Officer and
Investor Relations Manager

3+ years of experience

2023: Joins Predict in Finance & Control
Degree in Economics and Management, University of Trento



Giuseppe Carella
Director, Special Attorney
Director SBU Imaging

10+ years of experience

2014-today: Technical Assistance, Sales for Services, SBU People Support Service Manager, SBU Imaging Sales Manager
2024: Board Member of Predict
Master's degree in Chemistry, UniBA



Daniele Volpicella
Service Manager
SBU People Support


9 years of experience

2016: SBU Imaging Sales Manager 2024: SBU People Support Service Manager Diploma in Industrial Technical Expert with specialization in Electrical Engineering and Automation

PREDICT
LIFE CARE

SHAREHOLDING AND GOVERNANCE

SHAREHOLDING



Data updated as of 9th July 2026

***% on the total shares.**
- Qo3 S.r.l.: 76.47% of total shares | 69.01% ordinary shares | 83.94% voting rights
- Treasury shares: 0.62% of total shares | 0.82% ordinary shares | 0.42% voting rights
- Other shareholders**: 0.62% of total shares | 0.82% ordinary shares | 0.42% voting rights
- Market (float): 22.29% of total shares | 30.18% ordinary shares | 15.63% voting rights

** Other shareholders subject to lock-up restrictions. The lock-up has been lifted solely with respect to the future tranches of the Plan; the 48,000 shares relating to the 2025 tranche, credited on 6 July 2026, remain subject to the original 30-month lock-up period.

GOVERNANCE

Board of Directors**

Angelo Aurelio Gigante
President and CEO

Isabella Cafagna
Vice President, Executive Director

Loredana Amoruso
Executive Director

Rocco Dichio
Director

Valeria Stucci
Director

Giuseppe Carella
Director, Special Attorney

Vito Anelli
Independent Director

Board of Statutory Auditors**

- President: F. Sanseverino
- Statutory Auditor: R. Pierno
- Statutory Auditor: M. T. Rizzi
- Alternate Statutory Auditor: M. Secchi
- Alternate Statutory Auditor: V. Virzi

Supervisory Committee

- President: Atty. F. Di Marzio
- Atty. E. De Tommaso
- Atty. S. Pellegrino

Audit Firm***

BDO

Sustainability Report



Approved by the BoDs on March 23, 2026

**In office until the approval of the financial statements as of 31/12/2026
***In office until the approval of the financial statements as of 31/12/2027

GROWTH STRATEGIES





Development of innovative SBUs with a focus on Mistral

- R&D, partnerships with clinical research centers and university TTOs
- Hiring of new professional roles, strengthening of commercial functions, and product development
- Roll-out of a network of Mistral Labs in Italy
- Development of partnership agreements with pharmaceutical companies

Expansion of the hi-tech solutions offering

- Consolidation of the leadership position in the offering of hi-tech solutions through the expansion of the product range and the provision of training courses

Strengthening of traditional SBUs and cross-selling

- Diversification of product types, differentiating suppliers, and expanding the geographic markets served.
- Development of internal synergies to increase cross-selling activities between products and services to enhance customer loyalty and improve profitability


M&A

- Evaluation of potential acquisitions in breath analysis and digital healthcare to gain complementary know-how and expand market share


PREDICT LIFE CARE

FINANCIAL HIGHLIGHTS 1H26


Revenue / VoP (€mn)




EBITDA (€mn)




Net Result (€mn)



NFI / NFI Adj.* (€mn)




Equity (€mn)



*Adjustments attributable to receivables accrued under the regional PIA project, unchanged vs. 31/12/2025

INVESTMENT HIGHLIGHTS



PREDICT ON EGM

Market data

IDENTIFIERS & STOCK	
Stock code	PRE
ISIN Ordinary Shares	IT0005611071
N. Ordinary Shares	5,869,000
N. Multiple voting shares[1]	1,800,000
N. PAS[2]	60,000
IPO DATA	
Start date of trading	30/09/2024
Capital raised in IPO (pre greenshoe)	€ 1,519,500
Admission price	€ 1.00
IPO capitalization (ordinary shares)	€ 5,419,500
Euronext Growth Advisor / Specialist	Integrae SIM
DATA AS OF 30/09/2026	
Price	€ 1.01
Capitalization (ordinary shares)	€ 5,927,690

Analyst Coverage

Integrae SIM **TP:** €1.20
07/10/2026 **Rating:** BUY





1 Special category shares issued by the Company, not listed on Euronext Growth Milan, which grant the same rights and obligations as Ordinary Shares, except that each carries three voting rights and is converted into Ordinary Shares pursuant to the rules set forth in the corporate bylaws.
2 Special category shares issued by the Company, not listed on the Euronext Growth Milan market, which confer the same rights and obligations as Ordinary Shares, except that they are non-transferable and are automatically converted into Ordinary Shares under the terms and conditions set forth in the Company's bylaws.


Source: Borsa Italiana and Factset, data updated as of 30/09/2026

PREDICT
LIFE CARE

ANNEX


FINANCIAL HIGHLIGHTS FY25 vs FY24 & FY23

Revenue / VoP (€mn)




EBITDA (€mn)


EBITDA% FY25: 10.3%
(vs.12.2% FY24)




Net Result (€mn)



NFI / NFI Adj. (€mn)



Equity (€mn)



PREDICT
LIFE CARE

DISCLAIMER

This document has been prepared by Predict S.p.A. (the "Company") for informational purposes only. It contains only summarized information and, therefore, is of a preliminary nature. Additionally, it has been prepared without claiming to be exhaustive. This presentation ("Presentation") and the information contained therein ("Information"), unless with the prior written consent of the Company, may not be used by the recipient for any purpose, nor may they be disclosed, copied, recorded, transmitted, further distributed to any other person, or published, in whole or in part, by any means or in any form and for any purpose. This presentation may contain financial information and/or operational data and/or market information regarding the business and activities of the Company and its subsidiaries. THIS PRESENTATION AND ANY RELATED ORAL DISCUSSIONS DO NOT CONSTITUTE A PUBLIC OFFERING OR AN INVITATION TO SUBSCRIBE TO, PURCHASE, OR OTHERWISE ACQUIRE FINANCIAL PRODUCTS AS REFERRED TO IN ARTICLE 1, PARAGRAPH 1, LETTER (T) OF LEGISLATIVE DECREE NO. 58 OF 24 FEBRUARY 1998, AS AMENDED. Therefore, this document is not an advertisement and does not in any way constitute a proposal to execute a contract, an offer, or an invitation to purchase, subscribe to, or sell securities, and neither it nor any part of it constitutes the basis on which to rely in relation to any contract or commitment or investment decision. The Company has not prepared and will not prepare any prospectus for the purpose of the initial public offering of securities. Any decision to purchase, subscribe to, or sell securities shall be made independently of this Presentation. Therefore, no provision of this Presentation shall create any binding obligation or liability for the Company and its affiliates and their advisors or representatives. Likewise, the presentation is not intended for distribution in the United States of America, Canada, Australia, Japan, or any jurisdiction where such distribution is unlawful (as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act")). Neither this Presentation nor any copy of it may be taken or transmitted into the United States of America, its territories or possessions, or distributed, directly or indirectly, in the United States of America, its territories or possessions, or to any U.S. person. Failure to comply with this restriction may constitute a violation of U.S. securities laws. No statement or warranty, express or implied, is or will be given by the Company as to the accuracy, completeness, or correctness of the information provided, and, to the extent permitted by law and except in the case of fraud by the interested party, no liability is accepted for the accuracy or sufficiency thereof, or for errors, omissions, or inaccuracies, negligence, or otherwise, in relation thereto. In particular, but without limitation, no statement or warranty, express or implied, is or will be given as to the achievement or reasonableness of, and no reliance may be placed for any purpose on, the accuracy or completeness of estimates, objectives, projections, or forecasts and nothing in these materials should be considered as a promise or representation for the future. The information and opinions contained in this document are provided as of the date of this document and are subject to change without notice. The recipient will be solely responsible for its own assessment of the information contained in the Presentation. Neither the Company and its affiliates, nor their advisors or representatives shall be obliged to provide or update any information or to notify or correct any inaccuracies in any information. Neither the Company and its affiliates, nor any of their advisors or representatives shall have any liability to the recipient or any of its representatives as a result ofthe use or reliance on the information contained in this document. Some information may contain forward-looking statements that involve risks and uncertainties and are subject to change. In some cases, these forward-looking statements may be identified by the use of words such as "believe," "anticipate," "estimate," "target," "potential," "expect," "predict," "forecast," "project," "may," "should," "could," "shall," "will," "plan," "intend," "seek," and similar expressions. The forecasts and forward-looking statements included in this document are necessarily based on a number ofassumptions and estimates that are inherently subject to significant economic, operational, economic, and competitive uncertainties and unforeseen events, as well as assumptions relating to future business decisions subject to change. By their nature, forward-looking statements involve known and unknown risks and uncertainties, as they relate to events and depend on circumstances that may or may not occur in the future. Additionally, actual results may substantially differ from those contained in any forward-looking statement due to a number of significant risks and future events that are beyond the control of the Company and cannot be estimated in advance, such as the future economic environment and the actions of competitors and other parties involved in the market. These forward-looking statements speak only as of the date of this presentation. The Company cautions that forward-looking statements are not guarantees of future performance and that its current financial position, business strategy, plans, and management's objectives for future operations may differ materially from those contained or suggested by the forward-looking statements contained in this Presentation. Furthermore, even if the Company's financial position, business strategy, plans, and management's objectives for future operations are consistent with the forward-looking statements contained in this Presentation, such results or developments may not be indicative of results or developments in future periods. The Company expressly disclaims any obligation or commitment to disclose updates or revisions to any forward-looking statement contained herein to reflect any change in the Company's expectations in relation thereto or any change in events, conditions, or circumstances on which such statement is based. By receiving this Presentation, the user acknowledges and agrees to be bound by the above terms, conditions, limitations, and restrictions.

In case of any discrepancies or differences in interpretation between the Italian and English versions of the presentation, the Italian version shall prevail and be considered the most reliable.



PREDICT
Bari
Viale Adriatico, 4 c/o Fiera del Levante - Pad. 105 | +39 080 893 3754
Milano
Piazza Gae Aulenti 1, Torre B | +39 02 9713 0325
Roma
Via Marsala 29H | +39 06 4547 3124
predictcare.it

INVESTOR RELATIONS MANAGER
Angelo Ceci, CFO & IRM - Predict
E-mail: investor.relator@predictcare.it
Tel. +39 080 893 3754

INVESTOR RELATIONS ADVISOR
Chiara Cardelli, Senior Associate - KT&Partners
E-mail: ccardelli@ktepartners.com
Tel. +39 3387129015